• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma & Others) - Global Industry Analysis, Size, Growth, Trends & Forecast 2013 - 2019 Product Image

Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma & Others) - Global Industry Analysis, Size, Growth, Trends & Forecast 2013 - 2019

  • ID: 2642337
  • August 2013
  • Region: Global
  • 84 Pages
  • Transparency Market Research

FEATURED COMPANIES

  • Abbott Laboratories
  • Agendia NV
  • Agilent Technologies, Inc
  • BioGenex Laboratories Inc
  • bioMérieux SA
  • GE Healthcare Ltd
  • MORE

'Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma And Others) - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019'

This report studies the global market for companion diagnostics from two perspectives – companion diagnostics by indication and by geography. The market for companion diagnostics by indication includes sub-segments such as breast cancer, lung cancer, colorectal cancer, gastric cancer, melanoma and others (HIV, Thalassemia). By geography, the companion diagnostics market has been divided into four regions, namely, North America, Europe, Asia-Pacific and RoW.

Market size and forecast for each segment and sub-segment has been provided for the period 2011 to 2019 in terms of USD million, with 2012 as the base year. The compounded annual growth rate (CAGR) for each market segment has been provided for the forecast period 2013 to 2019.

The report also contains a section on market overview which consists of a detailed qualitative analysis of various market dynamics, such as drivers, restraints and opportunities. A section on market attractiveness analysis and Porter's READ MORE >

FEATURED COMPANIES

  • Abbott Laboratories
  • Agendia NV
  • Agilent Technologies, Inc
  • BioGenex Laboratories Inc
  • bioMérieux SA
  • GE Healthcare Ltd
  • MORE

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 List of Abbreviations

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Introduction
3.2 Market Drivers
3.2.1 Regulatory changes: The need for development of CDx along with targeted therapies
3.2.2 Increasing demand as well as developmental efforts towards personalized medicine
3.2.3 The pharmacoeconomic advantage: Reduced drug development costs
3.2.4 Increasing cancer incidence worldwide
3.2.5 Impact Analysis of Market Drivers
3.3 Market Restraints
3.3.1 Effect of influence of advocacy groups and clinical societies
3.3.2 Prolonged developmental and approval phases
3.3.3 Reimbursement scenario
3.3.4 Impact Analysis of Market Restraints
3.4 Market Opportunity
3.4.1 Expansion into newer indication areas
3.5 Porter's Five Forces Analysis: Global Companion Diagnostics Market
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyers
3.5.3 Threat of Substitutes
3.5.4 Threat of New Entrants
3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis: Global Companion Diagnostics Market, by Geography, 2012

Chapter 4 Companion Diagnostics Market, by Indication, 2011 - 2019 (USD Million)
4.1 Introduction
4.1.1 Comparative Analysis: Global Companion Diagnostics Market, by Indication, 2012 & 2019 (Value %)
4.1.2 Breast Cancer
4.1.2.1 Global Breast Cancer Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
4.1.3 Lung Cancer
4.1.3.1 Global Lung Cancer Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
4.1.4 Colorectal Cancer
4.1.4.1 Global Colorectal Cancer Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
4.1.5 Gastric Cancer
4.1.5.1 Global Gastric Cancer Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
4.1.6 Melanoma
4.1.6.1 Global Melanoma Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
4.1.7 Others (HIV, Thalassemia)
4.1.7.1 Global Other Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)

Chapter 5 Companion Diagnostics Market, by Geography, 2011 - 2019 (USD Million)
5.1 Overview
5.1.1 Comparative Analysis: Global Companion Diagnostics Market by Geography, 2012 & 2019 (Value %)
5.2 North America
5.2.1 North America Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
5.3 Europe
5.3.1 Europe Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
5.4 Asia-Pacific
5.4.1 Asia-Pacific Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
5.5 Rest of the World (RoW)
5.5.1 RoW Companion Diagnostics Market, Size and Forecast 2011 - 2019 (USD Million)

Chapter 6 Competitive Landscape
6.1 Market Share by Key Players, 2012 (%)

Chapter 7 Recommendations
7.1 Adoption of newer business models enabling co-developing companion diagnostics
7.2 Focus on research-intense investments

Chapter 8 Company Profiles
8.1 Abbott Laboratories
8.1.1 Company Overview
8.1.2 Financial Overview
8.1.3 Product Portfolio
8.1.4 Business Strategies
8.1.5 Recent Developments
8.1.5.1 FDA Approval
8.2 Agendia N.V.
8.2.1 Company Overview
8.2.2 Product Portfolio
8.2.3 Business Strategies
8.2.4 Recent Developments
8.3 Agilent Technologies, Inc.
8.3.1 Company Overview
8.3.2 Financial Overview
8.3.3 Product Portfolio
8.3.4 Business Strategies
8.3.5 Recent Developments
8.4 BioGenex Laboratories Inc.
8.4.1 Company Overview
8.4.2 Product Portfolio
8.4.3 Business Strategies
8.4.4 Recent Developments
8.5 bioMérieux SA
8.5.1 Company Overview
8.5.2 Financial Overview
8.5.3 Product Portfolio
8.5.4 Business Strategies
8.5.5 Recent Developments
8.6 GE Healthcare Ltd.
8.6.1 Company Overview
8.6.2 Financial Overview
8.6.3 Product Portfolio
8.6.4 Business Strategies
8.6.5 Recent Developments
8.7 Genomic Health, Inc.
8.7.1 Company Overview
8.7.2 Financial Overview
8.7.3 Product Portfolio
8.7.4 Business Strategies
8.7.5 Recent Developments
8.8 Life Technologies Corporation
8.8.1 Company Overview
8.8.2 Financial Overview
8.8.3 Product Portfolio
8.8.4 Business Strategies
8.8.5 Recent Developments
8.9 Qiagen N.V.
8.9.1 Company Overview
8.9.2 Financial Overview
8.9.3 Product Portfolio
8.9.4 Business Strategies
8.9.5 Recent Developments
8.10 Resonance Health Analysis Services Pty Ltd.
8.10.1 Company Overview
8.10.2 Product Portfolio
8.10.3 Business Strategies
8.10.4 Recent Developments
8.11 Roche Holdings AG
8.11.1 Company Overview
8.11.2 Financial Overview
8.11.3 Product Portfolio
8.11.4 Business Strategies
8.11.5 Recent Developments
8.12 Siemens Healthcare
8.12.1 Company Overview
8.12.2 Financial Overview
8.12.3 Product Portfolio
8.12.4 Business Strategies
8.12.5 Recent Developments

List of Figures

FIG. 1 Companion Diagnostics Market Segmentation
FIG. 2 Global Companion Diagnostics Market, by Indication, 2012 (USD Million)
FIG. 3 Porter's Five Forces Analysis: Global Companion Diagnostics Market
FIG. 4 Market Attractiveness Analysis: Global Companion Diagnostics Market, by Geography, 2012
FIG. 5 Comparative Analysis: Global Companion Diagnostics Market, by Indication, 2012 & 2019 (Value %)
FIG. 6 Global Breast Cancer Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
FIG. 7 Global Lung Cancer Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
FIG. 8 Global Colorectal Cancer Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
FIG. 9 Global Gastric Cancer Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
FIG. 10 Global Melanoma Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
FIG. 11 Global Other Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
FIG. 12 Comparative Analysis: Global Companion Diagnostics Market, by Geography, 2012 & 2019 (Value %)
FIG. 13 North America Companion Diagnostics Market, Size and Forecast, 2011 – 2019 (USD Million)
FIG. 14 Europe Companion Diagnostics Market, Size and Forecast, 2011 – 2019 (USD Million)
FIG. 15 Asia-Pacific Companion Diagnostics Market, Size and Forecast, 2011 – 2019 (USD Million)
FIG. 16 RoW Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
FIG. 17 Market Share Analysis: Global Companion Diagnostics Market, 2012 (%)
FIG. 18 Annual Revenues: Abbott Laboratories, 2010 – 2012 (USD Million)
FIG. 19 Annual Revenue: Agilent Technologies, Inc., 2010 – 2012 (USD Million)
FIG. 20 Annual Revenues: bioMérieux SA, 2010 – 2012 (USD Million)
FIG. 21 Annual Revenue: GE Healthcare Ltd., 2010 – 2012 (USD Million)
FIG. 22 Annual Revenues: Genomic Health Inc., 2010 – 2012 (USD Million)
FIG. 23 Annual Revenues: Life Technologies Corporation, 2010 – 2012 (USD Million)
FIG. 24 Annual Sales: Qiagen N.V., 2010 – 2012 (USD Million)
FIG. 25 Annual Revenues: Roche Holdings AG, 2010 – 2012 (USD Million) (1 CHF = 1.09 USD)
FIG. 26 Annual Revenues: Siemens Healthcare, 2010 – 2012 (USD Million)

List of Tables

TABLE 1 List of Abbreviations
TABLE 2 Market Snapshot: Global Companion Diagnostics Market
TABLE 3 Cancer Incidence, by Type, 2008 and 2015 (Million)
TABLE 4 Impact Analysis of Market Drivers
TABLE 5 Impact Analysis of Market Restraints
TABLE 6 Companion Diagnostics Required or Recommended by the U.S. FDA
TABLE 7 Global Companion Diagnostics Market, by Indication, 2011 - 2019 (USD Million)
TABLE 8 Breast Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
TABLE 9 Lung Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
TABLE 10 Colorectal Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
TABLE 11 Gastric Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
TABLE 12 Melanoma Companion Diagnostics (CDx), Manufacturers and Target Drugs
TABLE 13 Other Companion Diagnostics (CDx), Indications and Manufacturers
TABLE 14 Global Companion Diagnostics Market, by Geography, Size and Forecast, 2011 - 2019 (USD Million)

FEATURED COMPANIES

  • Abbott Laboratories
  • Agendia NV
  • Agilent Technologies, Inc
  • BioGenex Laboratories Inc
  • bioMérieux SA
  • GE Healthcare Ltd
  • MORE

Companion diagnostics facilitate the enhancement of a specific drug treatment by the patient's response at every stage of treatment. These tests specify whether the patient is likely to respond to the treatment or witness adverse reactions, and also enable optimization of dosing concentrations of the drug. The medications currently available commercially are becoming more and more personalized or targeted to specific patient populations. The development of a companion diagnostic along with the drug enables shortened drug development processes as its efficacy is already mapped by the patient outcomes. Hence, use of companion diagnostics increase the possibility of a drug attaining regulatory approval and also helps in evading long clinical trial design as only the targeted patient population needs to participate in the clinical trials.

The escalating costs involved in drug discovery and development have created a need for development of cost effective solutions. Many pharmaceutical companies are now focusing on the co-development of companion diagnostics along with the drug. This co-development strategy enables the commercialization of safer and efficient drug candidates. With the advent of personalized medicine and unfolding of human genome complexity, many pharmaceutical companies have reconsidered their current business models by moving away from ill-defined therapeutics to more specific personalized or targeted therapies.

Companion diagnostics provide insights about various issues associated with any type of drug treatment such as adverse reactions, toxicity and patient stratification. Pharmaceutical manufacturers are therefore focusing on development of tailor made therapies with the help of diagnostics manufacturers, in order to cater to the increasing demand for disease-specific therapies and defined target population. A large number of companion diagnostics are being developed in the field of oncology due to the continuous exploration of cancer-specific biomarkers, advanced technological platforms and large populations affected by different types of cancers.

Geographically, North America dominated the global companion diagnostics market in 2012 with a revenue share of over 35%. Technological advances, increased healthcare awareness, large consumer base, and better affordability for expensive diagnostic procedures are the major factors responsible for the region's leadership position. Factors such as major focus on rigorous research and development in the field of molecular diagnostics and presence of major market players are expected to drive growth of this market during the forecast period. Furthermore, in case of the Asian and Latin American markets, factors such as increasing awareness, rising number of cancer cases, developing infrastructure facilities and increasing acceptance of consumers towards novel approaches will enhance the uptake of companion diagnostics and drive market growth. On the other hand, factors which might hamper the growth of the overall companion diagnostics market are lack of well-defined regulatory guidelines for the development of companion diagnostics, prolonged developmental and approval processes and the need for high technology-based infrastructure to ensure highly sensitive detections.

- Abbott Laboratories
- Agendia NV
- Agilent Technologies, Inc
- bioMérieux SA
- BioGenex Laboratories Inc
- GE Healthcare Ltd
- Genomic Health, Inc
- Life Technologies Corporation
- Qiagen NV
- Resonance Health Analysis Services Pty Ltd
- Roche Holdings AG
- Siemens Healthcare

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos